The role of mTOR inhibitors and P13K pathway blockade in RCC

Michel Choueiri, Philip Mack

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The mammalian target of rapamycin (mTOR) is an important intermediary of the signaling transduction cascade that reacts to external nutrient abundance, to external growth factor and hormonal signaling, and to internal cellular energy levels. There are two major complexes formed with mTOR: mTORC1 and mTORC2. mTORC1 is rapamycin (also known as sirolimus) sensitive, and acts as a signaling intermediary for nutrient availability, energy levels, and growth factor signaling. mTORC2 is less well defined, and is capable of upregulating AKT activity. Two mammalian targets of rapamycin (mTOR) inhibitors were FDA approved for use in renal cell carcinoma (RCC) in the past 5 years. Temsirolimus, an intravenous sirolimus ester was shown to improve overall survival in a study of 626 patients with untreated metastatic RCC and poor risk features. Everolimus, an oral rapamycin analog, was shown to improve progression-free survival compared to placebo in patients with metastatic RCC who progressed on sorafenib, sunitinib, or both. New agents are being investigated that function upstream of mTOR to block activity of phosphoinositide-3 phosphate kinase (PI3K), AKT, or are capable of blocking mTORC1 and mTORC2 simultaneously.

Original languageEnglish (US)
Title of host publicationKidney Cancer: Principles and Practice
PublisherSpringer Berlin Heidelberg
Pages209-224
Number of pages16
ISBN (Electronic)9783642218583
ISBN (Print)9783642218576
DOIs
StatePublished - Jan 1 2012

Fingerprint

Sirolimus
Renal Cell Carcinoma
Intercellular Signaling Peptides and Proteins
Food
Disease-Free Survival
Esters
Phosphotransferases
Placebos
Survival
mechanistic target of rapamycin complex 1
TOR complex 2

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Choueiri, M., & Mack, P. (2012). The role of mTOR inhibitors and P13K pathway blockade in RCC. In Kidney Cancer: Principles and Practice (pp. 209-224). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-21858-3_14

The role of mTOR inhibitors and P13K pathway blockade in RCC. / Choueiri, Michel; Mack, Philip.

Kidney Cancer: Principles and Practice. Springer Berlin Heidelberg, 2012. p. 209-224.

Research output: Chapter in Book/Report/Conference proceedingChapter

Choueiri, M & Mack, P 2012, The role of mTOR inhibitors and P13K pathway blockade in RCC. in Kidney Cancer: Principles and Practice. Springer Berlin Heidelberg, pp. 209-224. https://doi.org/10.1007/978-3-642-21858-3_14
Choueiri M, Mack P. The role of mTOR inhibitors and P13K pathway blockade in RCC. In Kidney Cancer: Principles and Practice. Springer Berlin Heidelberg. 2012. p. 209-224 https://doi.org/10.1007/978-3-642-21858-3_14
Choueiri, Michel ; Mack, Philip. / The role of mTOR inhibitors and P13K pathway blockade in RCC. Kidney Cancer: Principles and Practice. Springer Berlin Heidelberg, 2012. pp. 209-224
@inbook{3912f3cd46154686bc00df6445aacdc6,
title = "The role of mTOR inhibitors and P13K pathway blockade in RCC",
abstract = "The mammalian target of rapamycin (mTOR) is an important intermediary of the signaling transduction cascade that reacts to external nutrient abundance, to external growth factor and hormonal signaling, and to internal cellular energy levels. There are two major complexes formed with mTOR: mTORC1 and mTORC2. mTORC1 is rapamycin (also known as sirolimus) sensitive, and acts as a signaling intermediary for nutrient availability, energy levels, and growth factor signaling. mTORC2 is less well defined, and is capable of upregulating AKT activity. Two mammalian targets of rapamycin (mTOR) inhibitors were FDA approved for use in renal cell carcinoma (RCC) in the past 5 years. Temsirolimus, an intravenous sirolimus ester was shown to improve overall survival in a study of 626 patients with untreated metastatic RCC and poor risk features. Everolimus, an oral rapamycin analog, was shown to improve progression-free survival compared to placebo in patients with metastatic RCC who progressed on sorafenib, sunitinib, or both. New agents are being investigated that function upstream of mTOR to block activity of phosphoinositide-3 phosphate kinase (PI3K), AKT, or are capable of blocking mTORC1 and mTORC2 simultaneously.",
author = "Michel Choueiri and Philip Mack",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-3-642-21858-3_14",
language = "English (US)",
isbn = "9783642218576",
pages = "209--224",
booktitle = "Kidney Cancer: Principles and Practice",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - The role of mTOR inhibitors and P13K pathway blockade in RCC

AU - Choueiri, Michel

AU - Mack, Philip

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The mammalian target of rapamycin (mTOR) is an important intermediary of the signaling transduction cascade that reacts to external nutrient abundance, to external growth factor and hormonal signaling, and to internal cellular energy levels. There are two major complexes formed with mTOR: mTORC1 and mTORC2. mTORC1 is rapamycin (also known as sirolimus) sensitive, and acts as a signaling intermediary for nutrient availability, energy levels, and growth factor signaling. mTORC2 is less well defined, and is capable of upregulating AKT activity. Two mammalian targets of rapamycin (mTOR) inhibitors were FDA approved for use in renal cell carcinoma (RCC) in the past 5 years. Temsirolimus, an intravenous sirolimus ester was shown to improve overall survival in a study of 626 patients with untreated metastatic RCC and poor risk features. Everolimus, an oral rapamycin analog, was shown to improve progression-free survival compared to placebo in patients with metastatic RCC who progressed on sorafenib, sunitinib, or both. New agents are being investigated that function upstream of mTOR to block activity of phosphoinositide-3 phosphate kinase (PI3K), AKT, or are capable of blocking mTORC1 and mTORC2 simultaneously.

AB - The mammalian target of rapamycin (mTOR) is an important intermediary of the signaling transduction cascade that reacts to external nutrient abundance, to external growth factor and hormonal signaling, and to internal cellular energy levels. There are two major complexes formed with mTOR: mTORC1 and mTORC2. mTORC1 is rapamycin (also known as sirolimus) sensitive, and acts as a signaling intermediary for nutrient availability, energy levels, and growth factor signaling. mTORC2 is less well defined, and is capable of upregulating AKT activity. Two mammalian targets of rapamycin (mTOR) inhibitors were FDA approved for use in renal cell carcinoma (RCC) in the past 5 years. Temsirolimus, an intravenous sirolimus ester was shown to improve overall survival in a study of 626 patients with untreated metastatic RCC and poor risk features. Everolimus, an oral rapamycin analog, was shown to improve progression-free survival compared to placebo in patients with metastatic RCC who progressed on sorafenib, sunitinib, or both. New agents are being investigated that function upstream of mTOR to block activity of phosphoinositide-3 phosphate kinase (PI3K), AKT, or are capable of blocking mTORC1 and mTORC2 simultaneously.

UR - http://www.scopus.com/inward/record.url?scp=84956808959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956808959&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-21858-3_14

DO - 10.1007/978-3-642-21858-3_14

M3 - Chapter

SN - 9783642218576

SP - 209

EP - 224

BT - Kidney Cancer: Principles and Practice

PB - Springer Berlin Heidelberg

ER -